ARTICLE | Product Development
Duvakitug leads to clinical remission in nearly half of UC patients
By Lauren Martz, Executive Director, Biopharma Intelligence
December 18, 2024 12:35 AM UTC
A third TL1A antagonist has excelled in a Phase II inflammatory bowel disease trial, reinforcing the class’ promise in the challenging indication and setting it up for a fiercely competitive commercial landscape.
Despite the availability of compelling biomarker signatures for predicting responses to the drug class, the new data suggest once again that all-comer efficacy signals may be strong enough to forge ahead without restricting patient populations — raising the perennial question of what it’s going to take to incentivize precision medicine…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654507/teva-sanofi-showcase-best-in-class-tl1a-potential-without-a-biomarker